Purpose: To correlate the area of geographic atrophy (GA) and residual foveal sparing (FS), and to identify the minimum FS and maximum GA area allowing sufficient visual acuity (VA) for daily tasks.
Design: Prospective cohort study.
Methods: Thirty-six eyes of 25 patients with GA and FS were followed for 18 months using spectral-domain optical coherence tomography and VA tests. Volume scans were imported into software enabling grading of areas in B-scans and computing of planimetric measurements in complete volume scans. Correlation of areas 1 (complete atrophy), 2 (FS in the central millimeter), and 3 (FS in the central 3 mm) with each other and with best-corrected VA (BCVA) were evaluated.
Results: Baseline means of areas 1, 2, and 3 were 6.15 mm, 0.49 mm, and 3.08 mm, respectively. At 1 year, area 1 increased by a mean of 1.33 mm, while areas 2 and 3 were decreased by 0.12 mm and 0.65 mm, respectively. From baseline to 18 months and from visit to visit, all areas and BCVA changed progressively (P < .001). Significant thresholds in GA size and FS for achieving a BCVA ≥ 70 ETDRS letters were detected (area 1: ≤6 mm; area 2: ≥0.48 mm; and area 3: ≥3.28 mm).
Conclusion: GA and FS changed inversely over time. In general, FS highly correlated with BCVA, while GA progression correlated with the central 3-mm FS regression, but not with BCVA. A threshold in GA and FS area could be determined for BCVA necessary for daily activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajo.2017.03.031 | DOI Listing |
Retin Cases Brief Rep
December 2024
Institute for Vision Research, Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City, IA 52242.
Purpose: To investigate the effect of macula-involving rhegmatogenous retinal detachment (RRD) repair on drusen regression.
Methods: A retrospective review was performed of patients with drusen who underwent macula-involving RRD repair. Longitudinal optical coherence tomography scans were reviewed by three graders, and each case was grouped into one of three categories: drusen regression, drusen persistence, or mixed.
J Manag Care Spec Pharm
January 2025
Humana Healthcare Research, Inc., Louisville, KY.
Background: Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that can lead to visual impairment. Published studies estimate approximately 1 million people in the United States have GA in at least 1 eye. There is a lack of real-world evidence from the US payer perspective on the prevalence of AMD and GA among Medicare Advantage prescription drug (MAPD) plan enrollees.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
January 2025
Humana Healthcare Research, Inc., Louisville, KY.
Background: Geographic atrophy (GA) is a form of advanced age-related macular degeneration (AMD) that can cause irreversible vision impairment and is responsible for approximately 20% of legal blindness in the United States. There is limited real-world evidence assessing health outcomes and health care resource use (HCRU) among individuals with GA.
Objective: To examine the progression from GA without subfoveal involvement (SFI) to GA with SFI, progression to irreversible blindness, and HCRU among older individuals with GA enrolled in Medicare Advantage Prescription Drug (MAPD) plans.
J Vitreoretin Dis
December 2024
Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
To evaluate the prevalence of geographic atrophy (GA) lesions in patients with a diagnosis of intermediate age-related macular degeneration (iAMD). A retrospective cross-sectional study was performed of patients with an International Classification of Diseases, 10th Revision, diagnosis of iAMD. The primary outcome was the percentage of eyes diagnosed with iAMD with an undocumented GA lesion identified on imaging.
View Article and Find Full Text PDFClin Ophthalmol
December 2024
Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USA.
Purpose: To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA).
Methods: This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!